During the 8-week treatment period, nine patients experienced SAEs: 0.3% (1/387) in the sacubitril/valsartan 200-mg group (subarachnoid hemorrhage), 0.3% (1/385) in the sacubitril/valsartan 400-mg group (arteriosclerosis of the coronary artery and hepatobiliary disease), and 1.8% (7/389) in the olmesartan group (alanine aminotransferase increased, bile duct stone, cataract, cerebral infarction, osteoarthritis, radius fracture, and supraventricular tachycardia). The gene discussed is GPT; the disease is subarachnoid hemorrhage.